J.P. Morgan

J.P. Morgan Offers Insight Into Incyte Corporation (INCY) Following 2015 Spring Biotech Conference Call

J.P.

Jason Cohen Jason Cohen — May 22, 2015, 2:54 PM EDT

J.P. Morgan Offers Commentary on Juno Therapeutics Inc Following 2015 Spring Biotech Conference Call

J.P.

Jason Cohen Jason Cohen — May 21, 2015, 3:00 PM EDT

J.P. Morgan Reiterates Overweight on bluebird bio Inc Following Global Regulatory Strategy Announcement for LentiGlobin

In a research report published Tuesday, J.P.

Corey Williams — May 19, 2015, 2:08 PM EDT

J.P. Morgan Maintains Overweight on Juno Therapeutics Inc Following 1Q:15 Update

J.P.

Jason Cohen Jason Cohen — May 13, 2015, 4:59 PM EDT

UPDATE: J.P. Morgan Reiterates Overweight on Vertex Pharmaceuticals Incorporated Following Positive FDA AdCom Recommendation

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares are up 8% in after-market trading after the FDA’s advisory committee panel recommended for approval the company’s ORKAMBI cystic fibrosis treatment. By …

Ben Mahaney, Editor — May 12, 2015, 5:58 PM EDT

J.P. Morgan Raises Red Flag on MannKind Corporation

Shares of MannKind Corporation (NASDAQ:MNKD) were hammered today after J.P.

Scott Fields Scott Fields — May 11, 2015, 1:19 PM EDT

J.P. Morgan Remains On The Sidelines With Ariad Pharmaceuticals, Inc. Following 1Q:15 Update

J.P.

Ben Mahaney, Editor — May 8, 2015, 11:22 AM EDT

J.P. Morgan Shines Light on Gilead Sciences, Inc. 1Q:15 Earnings

J.P.

Ben Mahaney, Editor — May 1, 2015, 7:28 AM EDT

J.P. Morgan Offers Commentary on Celgene Corporation Following Immuno-Oncology Collaboration With AstraZeneca

J.P.

Jason Cohen Jason Cohen — April 24, 2015, 4:43 PM EDT

J.P. Morgan Offers Commentary on Gilead Sciences, Inc. Following Discussion With COO John Milligan

J.P.

Ben Mahaney, Editor — April 7, 2015, 3:47 PM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts